SKYRAN BIOLOGICS, INC.

Skyran Biologics is a research and development company that is currently advancing an ophthalmic therapeutics platform to combat a number of important ocular diseases such as diabetic retinopathy or age-related macular degeneration. Rather than the injections directly into the eye that current treatments require, the company is developing a group of eyedrops that can treat a number of blinding eye diseases. Skyran Biologics was launched as a Delaware corporation in 2017 with Drs. Tombran-Tink and Barnstable as founders, building on Dr. Tombran-Tink's discovery of the neuroprotective molecule PEDF. The Skyran team has won an NIH STTR phase 1 grant converted into a phase II STTR grant to develop PEDF peptide mimetics, plus a separate Phase I STTR NIH grant to develop epigenetic modifiers as therapeutic agents to combat photoreceptor degenerative diseases.